|

|
Meeting
the Challenges of Global Oncology Trials
Dr. Ute Berger
Senior Director of Therapeutic Expertise
Oncology & Hematology
PRA International
Recording
- US$199
|
 |
Purchase
a recording of this Audio Conference
Successful
global oncology trials require careful planning, starting with
looking at the strategic elements that span people, process and
technology. Challenges in clinical research in oncology today
include multiple new agents for multiple new targets combined
with an increase in the number of patients needed to demonstrate
that a therapy provides a significant benefit for patients. There
is also a need to minimize the time it takes to go from basic
science discoveries into clinical studies. The risk posed by delays
in study start-up and patient recruitment can be mitigated by
proactively planning for the study.
Planning needs to reflect the traditional and nontraditional considerations
of feasibility and study design and incorporate trends and best
practices. Patient recruitment is a key strategic consideration,
along with epidemiological and genetic factors. Facilities, expertise
and other resources along with technology play a key role in global
trial planning.
Area-specific regulatory requirements vary in terms of standards
of care, and differences among healthcare systems influence trial
planning, as do local and cultural considerations.
This presentation will focus on the central challenges in global
oncology trials today and make recommendations about how they
might be addressed to mitigate risks in terms of timelines and
costs.
This
audio conference will cover:
- The importance
of a range of strategic considerations in planning global oncology
trials
- Recognizing
traditional and emerging or nontraditional considerations
- Understanding
how variances in the regulatory and service delivery environment
influence oncology trials
- How to
utilize a strategic approach to planning to best ensure successful
oncology trials
About
the speaker:
Ute
Berger, MD, is Senior Director of Therapeutic Expertise, Oncology
and Hematology, Scientific & Medical Affairs for PRA International,
a global CRO with 2,700 employees, covering 64 countries on six
continents.
She
earned her Doctor of Medicine degree from the University of Heidelberg
and has served in senior positions on the Faculty of Clinical
Medicine Mannheim, University of Heidelberg for more than 18 years.
She holds medical certifications in internal medicine, oncology
and hematology, and is certified by the European Society of Medical
Oncology (ESMO). Dr. Berger has also held numerous prestigious
and high-visibility professional positions, including Medical
Coordinator for the German CML Study Group; General Manager of
the German Competence Network “Acute and Chronic Leukemias”; and
Scientific Network Manager of the “European LeukemiaNet”. Dr.
Berger has particular expertise and a strong interest in clinical
research and has published extensively in prominent journals.
Dr.
Berger has established relationships with key opinion leaders
in the hematology/oncology field around the world. She has very
recent and relevant experience overseeing, directing and implementing
global oncology trials in a variety of indications.
Who should
attend?
- Heads of
Research and Development
- VPs of
Clinical Development
- Directors
of Clinical Operations
- Therapeutic
Area Leaders
- Program
and Clinical Study Managers
- Directors
of Outsourcing and Procurement
- VPs Global
Data Management
Purchase
Options:
|